Trial Profile

Phase 1/2a clinical trial to determine the maximum tolerated dose, safety, tolerability and early efficacy of rhenium (186Re) obisbemeda in supratentorial recurrent or progressive pediatric ependymoma and high-grade glioma (HGG)

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2025 According to a Plus Therapeutics media release, Dr. Ashley S. Plant is a Principal Investigator for the trial.
25 Jun 2025 According to a Plus Therapeutics media release, company announced that the trial is funded by a $3.0M research grant from the U.S. Department of Defense.
25 Jun 2025 According to a Plus Therapeutics media release, company announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com